JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS is a premier peer-reviewed journal published by Elsevier, dedicated to advancing the understanding of mutagenesis and its broader implications in genetics, health, and molecular biology. With an impressive converged publication history from 1964 to 2024, this journal provides a vital platform for the dissemination of high-quality research findings, contributing significantly to the field's knowledge base. Indexed in Scopus, it holds a Category Quartile ranking of Q3 in Genetics and Q2 in Health, Toxicology, and Mutagenesis, further underscoring its relevance and stature. Access options are available, catering to a diverse audience of researchers, professionals, and students eager to stay informed on the latest developments in mutagenesis research. By bridging experimental studies and theoretical frameworks, the journal plays a crucial role in exploring the fundamental mechanisms underlying genetic mutations and their effects on human health and the environment.

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

CURRENT ISSUES IN MOLECULAR BIOLOGY, published by MDPI, serves as an essential forum for researchers and professionals in the rapidly evolving field of molecular biology. Established in 1999 and operating under an Open Access model, this journal not only shares high-quality research but also encourages a vibrant exchange of ideas across various disciplines, including medicine and microbiology. With an impressive trajectory leading into 2024, it has earned its place in the Q2 quartile for both Medicine (miscellaneous) and Microbiology, emphasizing its relevance and impact in these areas. The journal’s commitment to disseminating cutting-edge findings is reflected in its diverse coverage of topics, from molecular genetics to microbial interactions. Operating from its home base in Basel, Switzerland, CURRENT ISSUES IN MOLECULAR BIOLOGY is positioned to contribute significantly to the academic landscape, making it indispensable for those seeking to advance their understanding and research within the life sciences.

Cellular and Molecular Biology is a prominent academic journal published by C M B ASSOC, specializing in the dynamic fields of cellular and molecular biology. Established in 1977, this journal has consistently aimed to disseminate groundbreaking research that contributes to our understanding of biochemical processes, cell dynamics, and molecular mechanisms governing life. With its ISSN 0145-5680 and E-ISSN 1165-158X, the journal plays a vital role in the exchange of innovative ideas, evidenced by its coverage of research from 1977 to 2024. Although currently categorized in the Q4 quartile for major disciplines such as Biochemistry and Cell Biology, it is dedicated to fostering the development of the field by welcoming submissions that challenge the conventional understanding and lead to novel insights. Researchers and academics looking to contribute to or stay updated in the rapidly evolving landscape of molecular biology will find this journal a valuable resource for connecting with a global community of scientists.

NATURE REVIEWS GENETICS, published by NATURE PORTFOLIO, stands as a leading journal in the field of genetics, boasting a remarkable reputation reflected in its Q1 ranking across multiple categories including Genetics, Clinical Genetics, and Molecular Biology. With an impressive percentile of 99th in both Genetics and Clinical Genetics, as well as a solid rank in Molecular Biology, this journal is pivotal for researchers, professionals, and students alike who seek to stay informed on the latest advancements and comprehensive reviews in genetic research. The journal's scope encompasses a wide array of topics, providing in-depth insights from fundamental genetic principles to clinical applications, underscoring its importance in bridging basic science and medical practice. Though not an open-access publication, it remains accessible through various academic institutions, enhancing its reach and influence within the scientific community. With publication years spanning from 2000 to 2024, NATURE REVIEWS GENETICS continues to shape the future of genetics research and education.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

BIOCHEMICAL GENETICS, published by Springer/Plenum Publishers, is a prominent journal in the fields of biochemistry, genetics, and molecular biology, with a substantial impact on the scientific community since its inception in 1967. The journal holds a significant position within various academic quartiles, ranking Q2 in Ecology, Evolution, Behavior and Systematics, and Q3 in Biochemistry, Genetics, and Medicine (miscellaneous), among others, demonstrating its diverse and interdisciplinary reach. With an ISSN of 0006-2928 and an E-ISSN of 1573-4927, it is recognized for contributing critical research insights and methodologies that drive the fields of biochemical genetics forward. Although it is not an Open Access journal, it provides vital access options and resources for researchers globally, facilitating the dissemination of knowledge across institutions. Positioned within the competitive landscape of Scopus rankings, it maintains respectable standings across its focused areas, making it an invaluable resource for researchers, professionals, and students seeking to deepen their understanding of genetic mechanisms and biochemical processes.

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.